[go: up one dir, main page]

WO2001017556A1 - Préparations vaccinales administrables par les muqueuses - Google Patents

Préparations vaccinales administrables par les muqueuses Download PDF

Info

Publication number
WO2001017556A1
WO2001017556A1 PCT/JP2000/005981 JP0005981W WO0117556A1 WO 2001017556 A1 WO2001017556 A1 WO 2001017556A1 JP 0005981 W JP0005981 W JP 0005981W WO 0117556 A1 WO0117556 A1 WO 0117556A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
carboxyvinyl polymer
antigen
formulation
mucosa
Prior art date
Application number
PCT/JP2000/005981
Other languages
English (en)
Japanese (ja)
Inventor
Shin-Ichi Fukanoki
Shigeru Tashima
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Publication of WO2001017556A1 publication Critical patent/WO2001017556A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • the present invention relates to a mucosa-applied vaccine preparation that acts on mucosal surfaces such as the nasal cavity and the oral cavity to effectively induce an antigen-specific immune response.
  • the preparation may contain, if desired, an appropriate amount or a trace amount of various agents and additives exemplified below, to the extent that the object and effects of the present invention are not impaired.
  • this preparation can be mixed with a carboxyvinyl polymer after the antigen has been subjected to preparation of a preparation such as coating, liposome formation, or microcapsule formation with a polymer or the like in advance.
  • Comparative Example 3 When this preparation was used, higher production of both serum IgG and secretory IgA was observed than the preparation of the comparative example prepared by neutralization in advance (Table 7). Therefore, if this product is submitted, it will be better than when a conventional vaccine formulation is used. Furthermore, it was revealed that the antigen-specific systemic immune system was more remarkably induced, and that the production of antigen-specific secretory IgA on the mucous membrane was promoted.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ces préparations vaccinales administrables par les muqueuses se caractérisent par le fait qu'elles contiennent un antigène et un polymère carboxyvinylique mais qu'elles sont exemptes de toute substance basique susceptible de neutraliser le polymère carboxyvinylique. L'utilisation de ces préparations favorise la production d'immunoglobuline G (IgG) par le système immunitaire systémique et renforce de manière significative la productivité de l'immunoglobuline A (IgA) sécrétoire.
PCT/JP2000/005981 1999-09-07 2000-09-04 Préparations vaccinales administrables par les muqueuses WO2001017556A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25273099 1999-09-07
JP11/252730 1999-09-07

Publications (1)

Publication Number Publication Date
WO2001017556A1 true WO2001017556A1 (fr) 2001-03-15

Family

ID=17241474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/005981 WO2001017556A1 (fr) 1999-09-07 2000-09-04 Préparations vaccinales administrables par les muqueuses

Country Status (1)

Country Link
WO (1) WO2001017556A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519037A (ja) * 2004-11-02 2008-06-05 ザ プロクター アンド ギャンブル カンパニー 気道用組成物の投与によってウイルス感染を捕捉、不活性化、及び除去するための方法
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7829273B2 (en) 2005-12-29 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US7829101B2 (en) 2004-12-30 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
US7914992B2 (en) 2007-01-03 2011-03-29 Boehringer Ingelheim Vetmedica, Inc. Treatment of PRDC in pigs
US7943298B2 (en) 2007-02-13 2011-05-17 Boehringer Ingelheim Vetmedica, Inc. Prevention and treatment of sub-clinical PCVD
US7951907B2 (en) 1997-12-05 2011-05-31 Wyeth Llc Circovirus sequences associated with piglet weight loss disease (PWD)
WO2011108521A1 (fr) * 2010-03-02 2011-09-09 国立大学法人徳島大学 Vaccin muqueux
US8119143B2 (en) 2005-12-29 2012-02-21 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US20120082697A1 (en) * 2009-03-31 2012-04-05 Japan As Represented By The Director General Of Natl. Inst. Of Infect Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
WO2013031827A1 (fr) * 2011-08-29 2013-03-07 国立大学法人徳島大学 Vaccin muqueux contre rsv
US8865183B2 (en) 2006-12-15 2014-10-21 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigent
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
US9561270B2 (en) 2009-09-02 2017-02-07 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity
US9636389B2 (en) 2006-12-11 2017-05-02 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and Lawsonia intracellularis infections
US9669086B2 (en) 2008-01-23 2017-06-06 Boehringer Ingelheim Vetmedica, Inc. PCV2 Mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US9919041B2 (en) 2004-12-30 2018-03-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US9987348B2 (en) 2013-09-25 2018-06-05 Zoetis Services Llc PCV2B divergent vaccine composition and methods of use
WO2025018848A1 (fr) * 2023-07-19 2025-01-23 주식회사 유틸렉스 Composition pour améliorer l'immunité, comprenant un lipopolysaccharide dérivé d'hafnia alvei et un carbomère

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63101318A (ja) * 1986-10-16 1988-05-06 Toko Yakuhin Kogyo Kk 点鼻剤
EP0391342A1 (fr) * 1989-04-05 1990-10-10 Toko Yakuhin Kogyo Kabushiki Kaisha Composition de gel à pulvériser, sa préparation et son utilisation
WO1994005330A1 (fr) * 1992-09-05 1994-03-17 The Procter & Gamble Company Produits pour pulverisateur nasal
JPH09157637A (ja) * 1995-10-06 1997-06-17 Osaka Ship Building Co Ltd エアゾール組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63101318A (ja) * 1986-10-16 1988-05-06 Toko Yakuhin Kogyo Kk 点鼻剤
EP0391342A1 (fr) * 1989-04-05 1990-10-10 Toko Yakuhin Kogyo Kabushiki Kaisha Composition de gel à pulvériser, sa préparation et son utilisation
WO1994005330A1 (fr) * 1992-09-05 1994-03-17 The Procter & Gamble Company Produits pour pulverisateur nasal
JPH09157637A (ja) * 1995-10-06 1997-06-17 Osaka Ship Building Co Ltd エアゾール組成物

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916353B2 (en) 1997-12-05 2014-12-23 Zoetis W Llc Circovirus sequences associated with piglet weight loss disease (PWD)
US10052375B2 (en) 1997-12-05 2018-08-21 Zoetics Services LLC Circovirus sequences associated with piglet weight loss disease (PWD)
US8415525B2 (en) 1997-12-05 2013-04-09 Zoetis W Llc Circovirus sequences associated with piglet weight loss disease (PWD)
US8124723B2 (en) 1997-12-05 2012-02-28 Wyeth Llc Circovirus sequences associated with piglet weight loss disease (PWD)
US8715690B2 (en) 1997-12-05 2014-05-06 Zoetis W Llc Circovirus sequences associated with piglet weight loss disease (PWD)
US9717784B2 (en) 1997-12-05 2017-08-01 Zoetis Services Llc Circovirus sequences associated with piglet weight loss disease (PWD)
US9700613B2 (en) 1997-12-05 2017-07-11 Zoetis Services Llc Circovirus sequences associated with piglet weight loss disease (PWD)
US7951907B2 (en) 1997-12-05 2011-05-31 Wyeth Llc Circovirus sequences associated with piglet weight loss disease (PWD)
JP2008519037A (ja) * 2004-11-02 2008-06-05 ザ プロクター アンド ギャンブル カンパニー 気道用組成物の投与によってウイルス感染を捕捉、不活性化、及び除去するための方法
US9919041B2 (en) 2004-12-30 2018-03-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US9011872B2 (en) 2004-12-30 2015-04-21 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7910306B2 (en) 2004-12-30 2011-03-22 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7829101B2 (en) 2004-12-30 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8025888B2 (en) 2004-12-30 2011-09-27 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US10576142B2 (en) 2004-12-30 2020-03-03 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8119143B2 (en) 2005-12-29 2012-02-21 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US9925255B2 (en) 2005-12-29 2018-03-27 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US10624963B2 (en) 2005-12-29 2020-04-21 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US10568955B2 (en) 2005-12-29 2020-02-25 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US7829273B2 (en) 2005-12-29 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US7968285B2 (en) 2005-12-29 2011-06-28 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9669087B2 (en) 2005-12-29 2017-06-06 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9987349B2 (en) 2005-12-29 2018-06-05 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9610345B2 (en) 2005-12-29 2017-04-04 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9011868B2 (en) 2005-12-29 2015-04-21 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US7838213B2 (en) 2005-12-29 2010-11-23 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9101561B2 (en) 2005-12-29 2015-08-11 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US9925256B2 (en) 2005-12-29 2018-03-27 Boehringer Ingelheim Vetmedica, Inc. Multivalent PCV2 immunogenic compositions and methods of producing such compositions
US7838214B2 (en) 2005-12-29 2010-11-23 Boehringer Ingelheim Vetmedical, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
US9636389B2 (en) 2006-12-11 2017-05-02 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and Lawsonia intracellularis infections
US8865183B2 (en) 2006-12-15 2014-10-21 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigent
US9517260B2 (en) 2006-12-15 2016-12-13 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigen
US7914992B2 (en) 2007-01-03 2011-03-29 Boehringer Ingelheim Vetmedica, Inc. Treatment of PRDC in pigs
US9522182B2 (en) 2007-01-03 2016-12-20 Boehringer Ingelheim Vetmedica, Inc. Prophylaxis and treatment of PRDC
US9555092B2 (en) 2007-02-13 2017-01-31 Boehringer Ingelheim Vetmedica, Inc. Prevention and treatment of sub-clinical PCVD
US8496940B2 (en) 2007-02-13 2013-07-30 Boehringer Ingelheim Vetmedica, Inc. Prevention and treatment of sub-clinical PCVD
US7943298B2 (en) 2007-02-13 2011-05-17 Boehringer Ingelheim Vetmedica, Inc. Prevention and treatment of sub-clinical PCVD
US9132187B2 (en) 2007-02-13 2015-09-15 Boehringer Ingelheim Vetmedica, Inc. Prevention and treatment of sub-clinical PCVD
US9132186B2 (en) 2007-09-04 2015-09-15 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
US8475805B2 (en) 2007-09-04 2013-07-02 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing concomitant infections in pigs with a PCV2 antigen
US9669086B2 (en) 2008-01-23 2017-06-06 Boehringer Ingelheim Vetmedica, Inc. PCV2 Mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US9603919B2 (en) * 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US20120082697A1 (en) * 2009-03-31 2012-04-05 Japan As Represented By The Director General Of Natl. Inst. Of Infect Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US9561270B2 (en) 2009-09-02 2017-02-07 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity
JP5804278B2 (ja) * 2010-03-02 2015-11-04 国立大学法人徳島大学 粘膜ワクチン
WO2011108521A1 (fr) * 2010-03-02 2011-09-09 国立大学法人徳島大学 Vaccin muqueux
WO2013031827A1 (fr) * 2011-08-29 2013-03-07 国立大学法人徳島大学 Vaccin muqueux contre rsv
JPWO2013031827A1 (ja) * 2011-08-29 2015-03-23 国立大学法人徳島大学 Ｒｓｖ粘膜ワクチン
US9987348B2 (en) 2013-09-25 2018-06-05 Zoetis Services Llc PCV2B divergent vaccine composition and methods of use
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
US11858963B2 (en) 2013-10-02 2024-01-02 Boehringer Ingelheim Animal Health USA Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
US12247051B2 (en) 2013-10-02 2025-03-11 Boehringer Ingelheim Animal Health USA Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
WO2025018848A1 (fr) * 2023-07-19 2025-01-23 주식회사 유틸렉스 Composition pour améliorer l'immunité, comprenant un lipopolysaccharide dérivé d'hafnia alvei et un carbomère

Similar Documents

Publication Publication Date Title
WO2001017556A1 (fr) Préparations vaccinales administrables par les muqueuses
Arca et al. Chitosan-based systems for the delivery of vaccine antigens
Florindo et al. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-ɛ-caprolactone-based nanoparticles
Lu et al. Pulmonary vaccine delivery
JP5124066B2 (ja) ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
Chua et al. Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines
JP4010462B2 (ja) インフルエンザワクチン組成物
US5674495A (en) Alginate-based vaccine compositions
JP6403738B2 (ja) デンプンを使用する経口ワクチン速溶性剤型
CN109364244B (zh) 黏膜佐剂和递送系统
JP2011190278A (ja) 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方
HUP0001838A2 (hu) Anyagok nyálkahártyán át történő beadása emlősöknek
JPH08508247A (ja) 粘膜表面への免疫原の輸送における重合的粘膜付着体
Zhao et al. Intranasal immunization with O-2′-Hydroxypropyl trimethyl ammonium chloride chitosan nanoparticles loaded with Newcastle disease virus DNA vaccine enhances mucosal immune response in chickens
Florindo et al. Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres
Florindo et al. New approach on the development of a mucosal vaccine against strangles: systemic and mucosal immune responses in a mouse model
EP1162945B1 (fr) Composition vaccinale a base de particules
CN118450903A (zh) 含有聚丙烯酸系聚合物的疫苗佐剂及其用途
WO2020099869A1 (fr) Nanoparticules et leurs utilisations
WO2020067302A1 (fr) Adjuvant muqueux
Elezaby et al. Mucosal vaccination through chitosan-based delivery systems
WO2011138050A1 (fr) Procédé de vaccination
Dobakhti et al. Immune response following oral immunization with BCG encapsulated in alginate microspheres
Lavelle et al. Mucosal Vaccines, Adjuvants and Delivery 2016-A Meetings Management Conference, Lausanne, Switzerland, September 14-16, 2016
Pandit Particulate carriers for vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 521344

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase